CAMBRIDGE, UK (02 Feb 2022) – Nuclera, a biotech company developing cutting-edge benchtop protein printing technologies, today announced that the first close of its Series B financing has raised $42.5 million. The funds raised will be used to accelerate the development and commercialization of its eProtein™ desktop bioprinter.
Nuclera’s ground-breaking protein printing technology has attracted many new and existing institutional and strategic investors in this financing round including M&G, Amadeus Capital Partners, E Ink, RT Partners, Future Planet Capital, British Business Bank Future…
Cambridge, UK, February 1, 2022 — Biofidelity, a pioneer in precision cancer diagnostics, has successfully completed a heavily oversubscribed $23 million Series A+ investment round, led by Octopus Ventures and backed by SBI Investment Co. Ltd. and existing investors. The investment will fund the upcoming launch of ASPYRE-Lung, the company’s first commercial diagnostic assay based on its breakthrough molecular technology.
ASPYRE is a completely new category of molecular diagnostic technology that simplifies and accelerates the detection of genomic biomarkers. The technology has been developed…
OXFORD, UK January 31, 2022 –PrecisionLife Limited, the global techbio company driving precision medicine in chronic disease with AI-led drug discovery, clinical development, and healthcare solutions, announces the first close of its Series A investment round. The financing, which is ongoing, will enable expansion and progression of its extensive and growing pipeline of commercial opportunities targeting complex chronic diseases. The company anticipates the second close of the Series A investment round in the coming months.
The investment will be used to expand the application of…
Edinburgh and Cambridge, UK, 24 January 2022 - Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, announces today that it has added five new internationally renowned Advisors to expand the immunology, oncology and clinical expertise within its advisory panel. The new additions from the Netherlands, France, Switzerland, the UK and Italy are Professor Karin de Visser, Dr Carlos Gomez-Roca, Professor Daniel Speiser, Professor Klaus Okkenhaug and Dr Mario Leonardo Squadrito.
They join Prof. Michele De Palma and Dr Jackie Doody world recognised experts in…
The Board of PIR International, a leading provider of executive search and interim services to the global life science industry, today announced the finalisation of an MBO with the executive team of the business, Sally Hope, Stuart Penney, and Tom Bradley, who will acquire the majority of shares from the founder, Carolyn Douthwaite.
Carolyn founded the business in 2006, initially focused on the provision of senior interims to major life science companies. Since then, the range of services has evolved, in line with client demand, and particularly the growth of the services to early stage,…
This cell culture supplement can be used to manufacture both autologous and allogeneic cell therapies
BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced the launch of its Good Manufacturing Practice (GMP) grade human AB serum, a cell culture supplement to enhance the development and manufacturing of cell and gene therapies.
“While there have been advancements in the field of serum-free media for cell and gene therapies, human AB serum has long been the ‘gold standard’ for rapid cell expansion. As the collection and production…
Innovate UK, the National Institute of Health Research (NIHR; i4i programme and AI in Health and Care Award) and the Small Business Research Initiative (SBRI) Healthcare have joined forces to offer specialist support to companies within their portfolios, from across the UK, via their Investment Readiness Programme. The programme will support selected companies to gain additional skills and expertise to get them prepared to find and attract investment.
Delivered by Bionow, the not-for-profit membership organisation, the Investment Readiness Programme has been specifically designed for UK…
Click here to read this month's People Pathways newsletter.
CAMBRIDGE, UK (18 Jan 2022) – Nuclera, a Cambridge, UK-based biotech company developing cutting-edge benchtop protein printing technologies, announces the opening of its US subsidiary located in Boston, MA.
The addition of this new US facility in the rapidly growing biotechnology hub of greater Boston USA is a critical step in the company’s plans and will pave the way for the delivery of Nuclera’s revolutionary eProtein™ desktop bioprinter, offering unprecedented speed and convenience for biotherapeutics, agribiotech and other markets of global importance. Nuclera’s eProtein™ bioprinter is…
Saffron Walden, 26th January 2022 / Sciad Newswire / Domainex Ltd., a leading provider of integrated drug discovery services to life science organisations globally, is delighted that Professors Daniel Longley, Tim Harrison and colleagues at Queen’s University Belfast have entered into a collaboration and licensing agreement with Ipsen. The agreement provides an exclusive licence to research, develop, manufacture and commercialise FLIP inhibitors. Domainex has supported the FLIP inhibitor programme from its inception.
At the start of the project, Domainex conducted a LeadBuilder virtual screen…